BRPI0811499A2 - Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral. - Google Patents

Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.

Info

Publication number
BRPI0811499A2
BRPI0811499A2 BRPI0811499-4A2A BRPI0811499A BRPI0811499A2 BR PI0811499 A2 BRPI0811499 A2 BR PI0811499A2 BR PI0811499 A BRPI0811499 A BR PI0811499A BR PI0811499 A2 BRPI0811499 A2 BR PI0811499A2
Authority
BR
Brazil
Prior art keywords
antigen
viral virus
purifying
preparing
methods
Prior art date
Application number
BRPI0811499-4A2A
Other languages
English (en)
Inventor
Manfred Reiter
Leopold Grillberger
Wolfgang Mundt
Artur Mitterer
Horst Schafhauser
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39596388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0811499(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of BRPI0811499A2 publication Critical patent/BRPI0811499A2/pt
Publication of BRPI0811499B1 publication Critical patent/BRPI0811499B1/pt
Publication of BRPI0811499B8 publication Critical patent/BRPI0811499B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14311Parvovirus, e.g. minute virus of mice
    • C12N2750/14351Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151Methods of production or purification of viral material
    • C12N2760/16152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16211Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251Methods of production or purification of viral material
    • C12N2760/16252Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Physics & Mathematics (AREA)
BRPI0811499A 2007-05-04 2008-04-30 métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral. BRPI0811499B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92769207P 2007-05-04 2007-05-04
US60/927692 2007-05-04
PCT/EP2008/003531 WO2008135229A2 (en) 2007-05-04 2008-04-30 Formulation of sugar solutions for continuous ultracentrifugation for virus purification

Publications (3)

Publication Number Publication Date
BRPI0811499A2 true BRPI0811499A2 (pt) 2014-10-14
BRPI0811499B1 BRPI0811499B1 (pt) 2019-06-04
BRPI0811499B8 BRPI0811499B8 (pt) 2021-05-25

Family

ID=39596388

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811499A BRPI0811499B8 (pt) 2007-05-04 2008-04-30 métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.

Country Status (18)

Country Link
US (4) US20100239609A1 (pt)
EP (1) EP2155864B1 (pt)
JP (2) JP5745717B2 (pt)
KR (4) KR101998537B1 (pt)
CN (2) CN104694489A (pt)
AR (1) AR066449A1 (pt)
AU (1) AU2008248904B2 (pt)
BR (1) BRPI0811499B8 (pt)
CA (1) CA2687119C (pt)
CL (1) CL2008001294A1 (pt)
HK (1) HK1211320A1 (pt)
IL (1) IL201898A (pt)
MX (1) MX2009011897A (pt)
PE (1) PE20090284A1 (pt)
RU (1) RU2503719C2 (pt)
TW (1) TWI472620B (pt)
WO (1) WO2008135229A2 (pt)
ZA (1) ZA200907743B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694489A (zh) * 2007-05-04 2015-06-10 巴克斯特国际公司 用于病毒纯化用连续超速离心的糖溶液配方
US20110293660A1 (en) * 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
CN101948813B (zh) * 2010-09-04 2012-07-25 国家海洋局第一海洋研究所 一种刺参球形病毒的分离方法
BE1023903B1 (fr) 2014-12-16 2017-09-08 Glaxosmithkline Biologicals Sa Nouveau procédé
EP3255054A1 (en) * 2016-06-06 2017-12-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the purification of biological macromolecular complexes
CA3040288A1 (en) * 2016-11-04 2018-07-12 Baxalta Incorporated Adeno-associated virus purification methods
MX2019010045A (es) 2017-03-03 2019-10-02 Baxalta Inc Metodos para determinar la potencia de preparaciones de virus adeno-asociados.
CN112198318B (zh) * 2020-07-15 2021-07-20 南京岚煜生物科技有限公司 抗体标准品赋值和抗体检测试剂最低检出限确定的方法
WO2022229703A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. New aav8 based immune escaping variants
WO2022229702A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. Aav8 capsid variants with enhanced liver targeting
AU2022364731A1 (en) * 2021-10-12 2024-05-02 Cytonus Therapeutics, Inc. Systems and methods for manufacturing of therapeutic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
DK187679A (da) * 1978-05-08 1979-11-09 Merck & Co Inc Fremgangsmaade til direkte ekstraktion af smaa partikler fra en proteinholdig vaeske
US4217418A (en) * 1978-05-08 1980-08-12 Merck & Co., Inc. Recovery of small particles by flow centrifugation
JPH06247995A (ja) * 1991-06-24 1994-09-06 Asahi Chem Ind Co Ltd 新規なシアリル(α2−6)ラクトテトラオシルセラミド
RU2080124C1 (ru) * 1995-10-19 1997-05-27 Санкт-Петербургский научно-исследовательский институт вакцин и сывороток Способ получения живой гриппозной вакцины
WO2004087760A1 (en) * 2003-04-01 2004-10-14 Inserm (Institut National De La Sante De La Reche Rche Medicale) Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
CN1739801A (zh) * 2004-08-27 2006-03-01 上海生物制品研究所 一种流行性感冒病毒裂解疫苗及其制备方法
CN104694489A (zh) * 2007-05-04 2015-06-10 巴克斯特国际公司 用于病毒纯化用连续超速离心的糖溶液配方

Also Published As

Publication number Publication date
TWI472620B (zh) 2015-02-11
EP2155864B1 (en) 2013-07-17
KR20150082676A (ko) 2015-07-15
RU2503719C2 (ru) 2014-01-10
KR20170065671A (ko) 2017-06-13
CA2687119C (en) 2021-06-08
JP6031082B2 (ja) 2016-11-24
HK1138318A1 (en) 2010-08-20
CL2008001294A1 (es) 2009-03-06
CN104694489A (zh) 2015-06-10
WO2008135229A2 (en) 2008-11-13
AR066449A1 (es) 2009-08-19
BRPI0811499B8 (pt) 2021-05-25
KR20180077305A (ko) 2018-07-06
TW200914615A (en) 2009-04-01
US20080274138A1 (en) 2008-11-06
CN101688187A (zh) 2010-03-31
AU2008248904B2 (en) 2014-10-09
AU2008248904A1 (en) 2008-11-13
KR101873891B1 (ko) 2018-07-04
WO2008135229A3 (en) 2008-12-31
HK1211320A1 (en) 2016-05-20
EP2155864A2 (en) 2010-02-24
US20160060603A1 (en) 2016-03-03
US20170369853A1 (en) 2017-12-28
US20100239609A1 (en) 2010-09-23
JP2015061538A (ja) 2015-04-02
KR101744430B1 (ko) 2017-06-20
RU2009144980A (ru) 2011-06-10
PE20090284A1 (es) 2009-03-17
US8969533B2 (en) 2015-03-03
IL201898A0 (en) 2011-08-01
BRPI0811499B1 (pt) 2019-06-04
ZA200907743B (en) 2010-09-29
KR20100017594A (ko) 2010-02-16
US9732327B2 (en) 2017-08-15
IL201898A (en) 2013-11-28
MX2009011897A (es) 2010-02-04
CA2687119A1 (en) 2008-11-13
JP2010525798A (ja) 2010-07-29
JP5745717B2 (ja) 2015-07-08
KR101998537B1 (ko) 2019-07-09

Similar Documents

Publication Publication Date Title
BRPI0811499A2 (pt) Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.
BRPI0809600A2 (pt) vírus atenuado útil para vacinas
IL248607A (en) Methods and compositions for immunization against virus
PL1858917T3 (pl) Szczepionka przeciw wirusowi ospy wietrznej i półpaśca
BRPI0716536A2 (pt) produÇço de vacinas de vÍrus influenza, sem a utilizaÇço de ovos
IL193397A0 (en) Hpv antigens, vaccine compositions, and related methods
BRPI1014322A2 (pt) Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
IL203869A (en) Method for the manufcture of a preparation comprising virus or viral antigens and various aspects related thereto, uses thereof and a split virus vaccine preparation obtained by the method
ZA200800505B (en) Modified influenza virus for monitoring and improving vaccine efficiency
CL2011000136A1 (es) Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c.
AP2008004625A0 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
HK1213478A1 (zh) 鱼用亚单位浸泡疫苗
BRPI0807597A2 (pt) Composição farmacêutica, e, método para tratar infecção por vírus da influenza
BRPI0818354A2 (pt) vacina preventiva do hiv baseada em anticorpos específicos para o hiv
IL213189A (en) Vaccine comprising avian influenza antigen, method of vaccinating an animal therewith, dna encoding the antigen and uses thereof
BR112014001049A2 (pt) método para a produção de um antígeno viral derivado de vírus envelopado, e, uso de um método para a fabricação de uma preparação de vacina contendo o antígeno viral
ZA200905952B (en) Lyophilized preparation comprising influenza vaccine,and method for preparation thereof
BRPI0810865A2 (pt) antígenos de tripanossoma, composições vacinais, e métodos relacionados
EA201001045A1 (ru) Модифицированный вирус гриппа
EP2178558A4 (en) YERSINIA PESTIS ANTIGENES, VACCINE COMPOSITIONS AND RELATED METHODS
AP2011005954A0 (en) Vaccine against African horse sickness virus.
ZA200809056B (en) Influenza virus vaccine
WO2007082734A3 (en) Influenza vaccine
WO2010040572A3 (en) Antibodies against h5n1 influenza viruses
WO2014008475A3 (en) Compositions and methods related to viral vaccines

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: BAXALTA GMBH (CH) , BAXALTA INCORPORATED (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/06/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)